Panama: The Rising Star of Medical Device Clinical Trials in Latin America
Introduction
In the heart of Central America, a small country is making big waves in medical device innovation. Panama, with its strategic location bridging North and South America, has emerged as an unexpected yet formidable player in clinical trials. This tropical nation, known for its famous canal and vibrant culture, is creating a new identity as a hub for cutting-edge medical research.
Imagine a place where state-of-the-art private hospitals stand alongside a comprehensive public health system, where regulatory approvals move at an impressive pace, and where diverse patient populations offer invaluable insights for global health innovations. This is the reality of Panama’s burgeoning clinical trial landscape.
With one of the fastest regulatory approval timelines in Latin America—spanning just 1-3 months—Panama is attracting the attention of multinational companies eager to expedite their research and development processes. The country’s commitment to fostering medical tourism has led to significant investments in healthcare infrastructure, creating an environment ripe for collaboration with U.S. and international firms.
As we delve into the intricacies of conducting medical device clinical trials in Panama, we’ll explore how this small nation is punching above its weight in the healthcare arena. From its robust regulatory framework to its cost-efficient operations, Panama offers a compelling case for why it should be on every medical device company’s radar. Join us on this journey through Panama’s clinical trial landscape, where innovation meets opportunity in the gateway of the Americas.
Overview of Panama’s Medical Infrastructure
Panama’s healthcare infrastructure, comprising both public and private sectors, is crucial in supporting clinical trials and developing new medical devices. The country is increasingly equipped to accommodate clinical research activities with its well-established hospitals, research centers, and commitment to high-quality care.
Panama has become a more appealing option for early feasibility studies (EFS) and first-in-human (FIH) trials, despite limitations in infrastructure compared to larger Latin American markets like Brazil and Colombia. The regulatory system is supportive but still maturing in experience with medical device trials, with efforts centered on Panama City’s primary hospitals, which offer the country’s highest standards in healthcare and research capabilities.
Contract Research Organizations (CROs) have established operations in Panama, providing end-to-end services for medical device companies looking to conduct trials in Latin America. These CROs leverage Panama’s centralized review process and maintain competitive pricing compared to U.S. and European markets, offering a cost-effective alternative for Medtech companies aiming to validate and scale new devices in diverse patient populations. Although the overall market size and infrastructure are smaller than in some other Latin American countries, Panama remains strategically important for Medtech trials due to its accessible regulatory environment and cost efficiency, making it a growing hub for CRO operations in the region.
Though Panama relies heavily on imported medical technology, the country has become increasingly involved in international clinical trials and is working toward becoming a regional medical tourism hub. This interest in fostering medical tourism has led to investments in state-of-the-art healthcare facilities and high-quality diagnostic tools, making Panama an attractive site for health innovation and research collaborations with U.S. and international companies. (1)
Panama’s Healthcare System
Panama operates a dual healthcare system, divided into public and private sectors, each serving distinct populations. The public healthcare sector is funded primarily through taxes and managed by two government agencies: the Social Security Fund (Caja de Seguro Social, or CSS) and the Ministry of Health (Ministerio de Salud, or MINSA). (2) CSS primarily provides healthcare services to citizens who contribute through payroll deductions, whereas MINSA operates public clinics and regional hospitals, offering low-cost essential services. (3)
The private sector complements the public system by providing access to world-class healthcare facilities that attract both Panamanian and international patients. Known for their quality and advanced capabilities, private hospitals in Panama, such as The Panama Clinic, Punta Pacifica Hospital, and Hospital Nacional, offer similar amenities and standards in the U.S. and Europe. (4) Punta Pacifica Hospital, for instance, is affiliated with Johns Hopkins Medicine International, enhancing its profile as one of Latin America’s most technologically advanced healthcare facilities. (4)
Availability of Hospitals and Research Facilities
Panama City, the capital, has several high-quality hospitals and research centers that can support clinical trials. Key institutions include:
Punta Pacifica Hospital: Affiliated with Johns Hopkins Medicine International, this facility is renowned for its advanced technology and extensive clinical capabilities, making it well-suited for complex medical trials.
Hospital Nacional: Known for specialized care and cutting-edge medical procedures, Hospital Nacional offers a strong foundation for conducting clinical research.
Hospital Santa Fe: This private hospital provides comprehensive healthcare services and is another key institution capable of supporting clinical trials. (5)
The Panama Clinic: The Panama Clinic is a modern healthcare facility housed within the Pacific Center complex. Its cutting-edge approach includes traditional and advanced medical services, supported by an adjacent hotel and shopping center for convenience to patients and medical tourists.
Clínica Hospital San Fernando: Panama’s first private hospital, San Fernando is affiliated with Miami Children’s Hospital and Baptist Health International. Known for its patient-centered care, it’s a popular choice among expats. It has additional facilities in Coronado, catering to beach communities. (6) (7)
Centro Médico Paitilla: This full-service hospital is noted for its oncology department and affiliations with Cleveland Clinic. Located in the Marbella neighborhood, it has served Panama’s community for decades, particularly with high-quality cancer care and advanced diagnostic services.
Many of these hospitals have established research facilities to manage various stages of clinical studies, from patient enrollment to data collection. For example, Punta Pacifica Hospital's research center houses multidisciplinary teams with clinical research and bioethics expertise, which is essential for conducting trials that are aligned with international standards. (4)
Robust Regulatory Framework Streamlines Approvals and Safeguards Ethical Standards
Panama has established itself as an attractive destination for medical device clinical trials. It offers a well-structured regulatory environment that balances efficiency, safety, and ethical oversight. The country's proactive approach to clinical trial governance has positioned it as a preferred location for international sponsors seeking to navigate the complexities of medical device development.
Centralized Regulatory Oversight
At the heart of Panama's clinical trial framework lies the Ministry of Health (Ministerio de Salud, MINSA), which oversees the regulation and approval of trials through its Medical Devices National Department and Pharmaceutical and Drug Department. (8) MINSA ensures that all clinical studies, particularly those involving medical devices, adhere to strict national standards for safety, efficacy, and ethics.
Complementing MINSA's role, the National Bioethics Committee (CNE) provides independent ethical oversight, reviewing proposed trials' moral and philosophical considerations of proposed trials. (8) This two-tiered system of regulatory and ethical review helps maintain the integrity of clinical data and the well-being of study participants.
Sequential Regulatory Pathway
Panama follows a sequential approval process for clinical trials, first requiring notification to MINSA and then submission to an accredited ethics committee (EC). (9) Sponsors of medical device clinical trials in Panama must first notify MINSA of the clinical trial, obtain a notification number, and then submit to one of the central accredited ECs chosen to review and approve the clinical trial.
Robust Ethics Committee System
ECs play a critical role in Panama's clinical trial framework, ensuring that studies adhere to the highest ethical standards. The country currently has 11 accredited ECs, each composed of a multidisciplinary team of professionals, including medical experts, ethicists, legal specialists, and laypersons. (10)
These ECs are responsible for evaluating the ethical soundness of proposed trials, with a particular focus on informed consent, risk management, and participant protection. They also ensure that informed consent forms are written in Spanish, making them accessible to the local population. (10)
Centralized ECs are particularly advantageous for multi-site studies, as they allow for a single ethical review to be applied across multiple locations. This streamlined approach helps maintain consistent ethical standards and reduces sponsors' administrative burdens. (10)
Aligning with International Best Practices
Panama's clinical trial regulations align closely with global industry standards, including the International Conference on Harmonisation (ICH) guidelines and Good Clinical Practice (GCP) principles. (9)
Key legislative measures, such as Law No. 90 of 2017, Law No. 84 of 2019, and Executive Decree No. 468 of 2007, provide a comprehensive framework for medical device trials, addressing safety, efficacy, and quality requirements. (9)
Panama's regulatory framework demonstrates a solid commitment to harmonizing its practices with international benchmarks. (11) This alignment safeguards participant well-being and ensures the acceptability of clinical data generated in the country, making it an appealing option for global medical device companies.
A Streamlined Pathway for Medical Device Trials
Centralized regulatory oversight, flexible approval processes, robust ethical review, and alignment with global best practices have transformed Panama into an attractive hub for medical device clinical trials. As the country continues to refine its regulatory landscape, it is poised to become an increasingly sought-after destination for international sponsors seeking to navigate the complexities of device development.
Factors Influencing Approval Timelines
While Panama's clinical trial approval process is generally predictable, several factors can influence the specific timelines:
Trial Complexity: Studies involving novel or high-risk medical devices often face extended review periods, as they require more rigorous scrutiny from ethics ECs in Panama. (9)
Regulatory Responsiveness: Panama's regulatory bodies, including MINSA and the accredited ECs, are largely known for their cooperative approach. However, responsiveness can be affected by fluctuations in the volume of submissions and available resources. (9)
Legal and Regulatory Updates: In 2019, Panama enacted Law 84, which streamlined the approval process. This regulatory reform was intended to enhance the country's appeal as a medical device and pharmaceutical research destination. (9)
Although a growing hub for clinical research, Panama faces challenges with patient recruitment due to its small population and limited number of research-ready hospitals. However, the regulatory landscape has been improving with streamlined protocols for clinical trial approvals, especially since Panama’s clinical research law update in 2019. Another Panama challenge is navigating EC review and approval, which can occasionally delay trial approvals and complicate the logistics of clinical studies. (2) Additionally, healthcare access in rural areas is limited, posing challenges for clinical trials that require diverse participant pools across different geographic regions. (4)
A Cost-Efficient Destination for Medical Device Development
Leveraging Diverse Patient Populations and Streamlined Processes
As the medical device industry evolves, sponsors increasingly seek strategic locations offering regulatory efficiency and cost-effective implementation. In this regard, Panama has emerged as an attractive hub, boasting a diverse patient demographic and a streamlined clinical trial framework that can translate to significant savings.
Diverse Patient Pool
Panama's population of approximately 4.4 million people provides a diverse pool of potential participants for clinical trials, offering a range of ethnic backgrounds and health profiles. (9) This diversity is particularly beneficial for medical device studies, as it allows researchers to evaluate the performance and safety of new technologies across a broad spectrum of patient characteristics.
The country's population is composed of mestizo, Indigenous, and Afro-Panamanian groups, providing a genetic diversity that can be valuable for trials requiring a representative sample. (9) Additionally, Panama's high urbanization rate, with around 68% of the population concentrated in the capital region, facilitates access to participants in the areas where most medical research facilities are located. (9)
Targeted Recruitment Strategies for Efficient Enrollment
To effectively reach and engage potential trial participants, sponsors in Panama often employ community-based recruitment methods that leverage trusted local relationships. (12) This approach involves partnering with healthcare providers, community leaders, and even local organizations to educate potential participants and address any concerns about clinical research.
In addition to community outreach, digital recruitment strategies are also gaining traction. Sponsors are utilizing social media and targeted online campaigns to broaden their reach, particularly in urban centers where internet access is more prevalent. (13) The integration of specialized patient recruitment firms further streamlines the enrollment and pre-screening processes, improving efficiency and reducing overall costs.
Cost Savings
Panama's clinical trial ecosystem offers significant cost advantages compared to more developed markets like the United States and Europe. These savings are realized across various aspects of the trial implementation process:
Regulatory Fees: The country's streamlined regulatory framework, introduced under Law 84 of 2019, has reduced administrative costs and expedited approval timelines; this is especially true for Medtech startup companies sponsoring first-in-human and early feasibility studies. (14)
Recruitment Costs: Lower labor costs and the ability to leverage community-based outreach strategies help optimize patient recruitment resources, reducing time and expenses. (12) (13)
Operational Expenses: Panama's lower cost of living translates to savings on facility rentals, equipment, and staffing, while the country's compact geography and centralized medical infrastructure minimize logistical challenges and associated costs. (14)
Incentives for R&D: The Panamanian government offers various tax incentives and exemptions for research and development activities, further offsetting the operational expenses for foreign sponsors. (14)
Success Stories of Medical Device Trials in Panama
Several recent medical device trials conducted in Panama have demonstrated the country's growing prominence in this field. These case studies highlight the diverse therapeutic areas and innovative technologies that have found a home in the Panamanian research ecosystem.
· Optilume Drug-Coated Balloon by Urotronic, Inc.: In 2022, Urotronic, Inc. completed a first-in-human trial of its Optilume drug-coated balloon to treat recurrent urethral strictures in men. (15) The study, conducted in Panama, showcased the potential of the Optilume device to reduce the recurrence of this condition, which often requires repeated surgical interventions. Panama's regulatory efficiency and centralized ethics review process facilitated the expedited initiation of this groundbreaking trial.
· RUE Vascular Graft by Vascudyne, Inc.: In 2021, Vascudyne, Inc. tested its regenerative vascular graft to enhance vascular access for patients with end-stage renal disease undergoing hemodialysis. (16) The trial, which took place in Panama, highlighted the device's ability to improve treatment adherence and reduce vascular access-related complications. The study leveraged Panama's accessible urban patient population and supportive regulatory infrastructure, demonstrating the country's capacity to handle complex vascular and regenerative medicine studies.
· Neurotronic, Inc.: This clinical trial assesses the safety and efficacy of the Neurotronic Infusion Catheter for treating Type 2 diabetes, hypertension, and obesity through renal and hepatic artery denervation. The study is open-label (no masking), and the intervention is chemical denervation of renal and hepatic arteries using the Neurotronic Infusion Catheter. The study involves multiple locations in Panama and Paraguay. (17)
The success of these trials in Panama has had profound implications for patient health, particularly for individuals suffering from chronic and life-limiting conditions.
Conclusion
As we conclude our exploration of Panama’s burgeoning medical device clinical trial landscape, it’s clear that this small Central American nation is punching well above its weight in the global healthcare arena. Panama has transformed itself into a beacon of innovation and efficiency in the clinical research world, offering a unique blend of strategic advantages that are hard to overlook.
The country’s commitment to streamlining regulatory processes, robust healthcare infrastructure, and diverse patient populations create a fertile ground for groundbreaking medical device trials. From the bustling research centers in Panama City to the collaborative spirit of its healthcare professionals, Panama is writing a new chapter in the story of medical innovation.
Panama presents a compelling proposition for medical device companies seeking to accelerate their path to market while maintaining rigorous scientific standards. Its cost-effective operational environment, coupled with regulatory timelines that are among the fastest in Latin America, offers a competitive edge in the Medtech industry, where time and resources are often at a premium.
The success stories emerging from Panama’s clinical trial ecosystem testify to its growing capabilities. From innovative urological devices to cutting-edge vascular grafts, the country has demonstrated its ability to support complex, high-impact studies that potentially transform patient care globally.
As we look to the future, Panama’s trajectory in the clinical trial space appears to be steeply upward. With continued investment in healthcare infrastructure, a commitment to regulatory excellence, and an unwavering focus on patient well-being, Panama is poised to become an even more integral player in the global medical device industry.
For those at the forefront of medical device innovation, the message is clear: Panama is not just a country to watch—it’s a destination to seriously consider for your next clinical trial. In the heart of the Americas, a new hub of medical innovation is rising, and its name is Panama.
References
1. Healthcare Resource Guide - Panama. International Trade Administration. [Online] [Cited: November 9, 2024.] https://www.trade.gov/healthcare-resource-guide-panama.
2. Insurance, International. Panama Healthcare System: Pros, Cons and Challenges. International Insurance. [Online] 11 05, 2024. https://www.internationalinsurance.com/health/systems/panama/.
3. Chiasson, Vanessa. 7 Things You Need To Know About Healthcare In Panama . travelawaits. [Online] 10 14, 2024. https://www.travelawaits.com/2678379/things-you-need-to-know-about-healthcare-in-panama/.
4. Group, Oxford Business. Panama improves access to health care system . oxfordbusinessgroup. [Online] 11 23, 2018. [Cited: 11 4, 2024.] https://www.oxfordbusinessgroup.com/analysis/panama-improves-access-health-care-system .
5. Web, Boldly Panama. Healthcare in Panama | The Ultimate Guide. Boldly Panama . [Online] [Cited: 11 05, 2024.] https://www.boldlypanama.com/healthcare-in-panama-the-ultimate-guide/.
6. Best 5 Hospitals In Panama City, Panama. My Latin Life. [Online] May 3, 2022. [Cited: November 9, 2024.] https://mylatinlife.com/2022/05/03/best-5-hospitals-in-panama-city/.
7. Healthcare in Panama. Boldly Panama. [Online] [Cited: November 9, 2024.] https://www.boldlypanama.com/healthcare-in-panama-the-ultimate-guide/.
8. PharmaBoardroom. The Pharma Legal Handbook: Panama. pharmaboardroom. [Online] 07 09, 2023. [Cited: 11 05, 2024.] https://www.pharmaboardroom.com.
9. Martinez-Clark, Julio G. Exploring Panama’s Landscape for Medical Device Trials. Bioaccess LATAM CRO Experts. [Online] [Cited: 11 05, 2024.] https://www.bioaccessla.com/blog/exploring-panamas-landscape-for-first-in-human-and-early-feasibility-medical-device-clinical-trials.
10. —. Understanding Medical Device Clinical Trial Regulations. [Online] [Cited: 11 04, 2024.] https://blog.bioaccessla.com/understanding-medical-device-clinical-trial-regulations/.
11. Gómez, Dr. Ricardo. Panama's Regulatory Framework for Clinical Trials. Clinical Trials and Research. [Online] 2023. [Cited: 11 05, 2024.] https://clinicaltrials.gov/panama-regulatory-framework.
12. Clinical, H. The Importance of Building Trust in Latin America. [Online] 2020. [Cited: 11 04, 2024.] https://www.hclinical.com.
13. Martinez-Clark, Julio G. 8 Effective Patient Recruitment Strategies for Clinical Trials. blog bioaccessla. [Online] 2023. [Cited: 11 05, 2024.] https://blog.bioaccessla.com.
14. Leader, Clinical. Latin America's Landscape For Medtech Clinical Trials. Clinical Leader. [Online] 2021. [Cited: 11 04, 2024.] https://www.clinicalleader.com.
15. Urotronic, Inc. Urotronic Announces Completion of First-in-Human Clinical Trial of Optilume Drug Coated Balloon in Panama. Urotronic. [Online] 2022. [Cited: 11 05, 2024.] https://www.urotronic.com.
16. Vascudyne, Inc. Vascudyne Announces Successful First-in-Human Clinical Trial of TRUE Vascular Graft in Panama. https://www.vascudyne.com. [Online] 2021. [Cited: 11 05, 2024.] https://www.vascudyne.com.
17. Arterial Ablation for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities (NECTAR III). Clinicaltrials.gov. [Online] March 21, 2023. [Cited: November 9, 2024.] https://clinicaltrials.gov/study/NCT05363761?locStr=Panama&country=Panama&term=Medical%20Device&limit=50&aggFilters=phase:1%200&rank=1.
18. Health, Lindus. The Importance of Clinical Trials in Medical Devices . lindushealth. [Online] 11 05, 2024. https://www.lindushealth.com/blog/the-importance-of-clinical-trials-in-medical-devices .
19. NuVera Medical Announces Successful First-in-Human Clinical Trial of NuVision Intracardiac Echocardiography Catheter in Panama. Nuvera medical. [Online] 2020. [Cited: 11 04, 2024.] https://www.nuveramedical.com.
